Mamosis has developed an AI-powered software platform that analyzes mammography images in roughly five seconds and provides physicians with decision support at better than 90% accuracy, all without requiring additional hardware or changes to existing hospital infrastructure. The cloud-based system is PACS-compatible and accessible via web and mobile interfaces, and it is already being piloted in multiple private hospitals while clinical studies continue across eight clinics. Leveraging continuous learning algorithms, the product improves its diagnostic performance over time. With the newly secured capital, the company plans to broaden its scope beyond breast cancer to include skin, lung and prostate cancers. A large share of the funding is earmarked for R&D, while the remainder will accelerate commercial rollout across Turkey and support international sales and marketing through its offices in the UK and Dubai. The recent raise valued the company at 40 million TL, underscoring investor confidence in its rapid, hardware-free integration model. Mamosis positions itself as a faster and more user-friendly alternative to other AI-based cancer detection solutions on the market.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2025